ADIL - Adial Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$1.83

$-0.14 (-7.11%)

About Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

ADIL Key Statistics

Market Cap

$2.19M

0

P/B Ratio

0.49

EPS

$-15.00

Employees

5

How ADIL Compares to Peers

ADIL is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

#6

of 6

CompanyP/EGrowthCompare
ADILN/A0%-
AMGN25.80%vs AMGN
GILD21.40%vs GILD
VRTX30.10%vs VRTX
REGN18.50%vs REGN
BIIB21.4-0%vs BIIB

Adial Pharmaceuticals Inc Company Information

Headquarters
Virginia; U.S.A
Website
www.adial.com
Sector
Health Care
Industry
Biotechnology
Data Updated:
Ready to invest in ADIL?

Commission-free trading available. Affiliate links.

ADIL Lician Score

5% confidence
4.0/10
Neutral

ADIL has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ADILacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ADIL Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

35810Value5.0Growth2.0Quality5.0Momentum5.0Safety5.04.4/10
5.0

Value

2.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for ADIL